



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

Info: info@igbamedicines.org

Lucas Sigman and Allan Oberman appointed 2025 Chair and Vice-Chair of the IGBA CEO Advisory Committee

For immediate release

Geneva, 19 December 2024

The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Lucas Sigman, CEO of Insud Pharma, has been appointed Chair and Allan Oberman, President and CEO of Apotex, Vice-Chair.

The CEO AC is composed of fifteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States. This Committee provides a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues.

“After a year as Vice-Chair, I am excited to take over chairmanship of IGBA’s CEO Advisory Committee and I look forward to working on the strengthening of the generic and biosimilar medicines industry in 2025,” commented Lucas Sigman, adding “The industry still faces important challenges on regulatory harmonization, supply chain, and drug shortages, and we will keep focusing on finding the right approaches to navigate them. For 2025, we have a unique opportunity to advance the work related to the industry’s sustainability, balanced intellectual property systems, and international convergence and harmonization, contributing to enhancing access to safe, effective, more affordable quality-assured medicines.”

Lucas Sigman will succeed Vinita Gupta, CEO of Lupin. “The IGBA Management Committee is thankful for Vinita’s leadership during 2024, year in which IGBA increased its external engagements and focused on important issues such as access to medicines, regulatory convergence, balanced IP systems, and fair markets” said Adrian van den Hoven, the Chair of IGBA’s Management Committee, adding “Her work and commitment have been instrumental in shaping IGBA’s current projects, including on intellectual property and regulatory harmonization.”

“IGBA is well positioned to help enable the adoption of generic and biosimilar medicines globally, and to be a critical voice for universal health coverage and widespread access to effective and affordable

About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org

medicines,” commented Vinita Gupta. “I am confident that IGBA will continue to advance initiatives to enhance our industry’s sustainability and drive key stakeholder engagement,” she concluded.

About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org